SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-24-114056
Filing Date
2024-04-25
Accepted
2024-04-25 16:40:00
Documents
1
Group Members
FAIRMOUNT HEALTHCARE FUND II LPPETER HARWINTOMAS KISELAK

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d820181dsc13da.htm SC 13D/A 85421
  Complete submission text file 0001193125-24-114056.txt   87285
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Subject) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89456 | Film No.: 24877053
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428
Business Address 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 267-262-5300
Fairmount Funds Management LLC (Filed by) CIK: 0001802528 (see all company filings)

IRS No.: 364841215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A